• patient aged ≥ 5 years old and \< 18 years old

• patient able to receive sonications and perform MRI studies without sedation

• diagnosis of supra-tentorial primary malignant brain tumor (e.g. malignant glioma, embryonal tumor including ATRT, ependymoma)

• recurrence or progression of brain tumor after at least a first line of standard treatment (multifocal tumors and metastatic disease allowed)

• indication of treatment with carboplatin, validated in multidisciplinary meeting

• Karnofsky performance scale index (patients ≥ 16 years old) or Lansky performance status (patients \< 16 years old) \> 50% (a patient with a performance status score altered by a motor deficit due to tumor infiltration will be allowed to be included)

• no threat of brain herniation or uncontrolled intracranial hypertension

• corticosteroids treatment ≤ 1mg/kg/day

• neutrophils \> 1.5 x 109/L

• platelets \> 100 x 109/L

• total bilirubin \< 1.5x upper limit of normal, AST et ALT \< 2.5x upper limit of normal

• serum creatinin \< 1.5x upper limit of normal for the age or creatinine clairance \>70mL/min/1.73m2 (EDTA method or 24h urine)

• coagulation parameters in the normal limits for age (fibrinogen, prothrombin time and activated clotting time)

• no grade 2 or more toxicity depending on the NCI-CTCAE v5.0 criteria

• no healed wound on the scalp

• covered by health insurance

• for patients of chilbearing age (15-17 years old) : a negative pregnancy test and an efficient method of birth control

• written consent signed by the patient (if possible) and his parents or legal representatives.